Wln: GA N-O3*3

Base Information

• Chemical Name: Wln: GA N-O3*3
• CAS No.: 13494-90-1
• Molecular Formula: Ga. 3 H N O3
• Molecular Weight: 255.75
• NSC Number: 15200
• Mol file: 13494-90-1.mol

Synonyms:NCI60_001065;WLN: GA N-O3*3

Chemical Property of Wln: GA N-O3*3

Chemical Property:

• Melting Point: 110°C (dec.)
• Boiling Point: 83°Cat760mmHg
• Flash Point: °C
• PSA: 206.64000
• Density: 1.623g/cm³
• LogP: 0.80900
• Water Solubility.: It is soluble in water.
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 0
• Exact Mass: 131.92122
• Heavy Atom Count: 5
• Complexity: 24.8

Purity/Quality:

98% ^*data from raw suppliers

GALLIUM NITRATE 95.00% ^*data from reagent suppliers

Safty Information:

• Statements: 8-36/37/38
• Safety Statements: 17-26-36/37/39

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: [N+](=O)(O)[O-].[Ga]
• Description: Gallium nitrate, initially developed as an anticancer agent, was introduced by Fujisawa as an orphan drug for the treatment of cancer-related hypercalcemia and bone metastases that do not respond to adequate hydration. The compound acts specifically on bone by inhibiting calcium resorption and also possibly by stimulating bone formation. Compared with calcitonin and etidronate, gallium nitrate is more potent and substantially longer acting. Other potential uses could be in the treatment of osteoporosis and Paget’s disease.
• Uses: Gallium is the second metal ion with clinical activity used in cancer treatment. Gallium nitrate has demonstrated antitumor activity in a variety of murine tumor models, including Walker 256 carcinosarcoma, fibrosarcoma M-89, leukemia K-1964, adenocarcinoma 755, mammary carcinoma YMC, reticulum cell sarcoma A-RCS, lymphoma P1798, and osteosarcoma 124F. It was, however, ineffective in ascites, leukemias, plasma cell tumors, or Ehrlich carcinoma. In phase II evaluation studies, gallium nitrate has shown antitumor activity in patients with either refractory lymphomas or small-cell lung carcinomas or bladder cancer, with total objective response rates of 28% and 11%, respectively. This drug has displayed its strongest antineoplastic activity in the treatment of non-Hodgkin’s lymphoma and bladder cancer. In addition, according to two phase III comparative trials,thanks to an inhibitory effect on calcium reabsorption from bone, gallium nitrate is superior to alternative therapies in the treatment of hypercalcemia associated with malignancy and related disease states. Based on its clinical efficacy, gallium nitrate (Ganite ) was approved by the Food and Drug Administration (FDA) for the treatment of cancerassociated hypercalcemia.Apart from its ability to control hypercalcemia, gallium nitrate has been shown to inhibit bone turnover and decrease osteolysis in patients with multiple myeloma and in patients with bone metastases from a variety of different cancers. Gallium(III) nitrate solution, is used as the material for producing gallium salts and for scientific research and chemical reagent. It is also used as an intermediate. Regulator (calcium).